Literature DB >> 15775706

Effect of aspirin and acetaminophen on proinflammatory cytokine-induced pain behavior in mice.

Min-Soo Kwon1, Eon-Jeong Shim, Young-Jun Seo, Seong-Soo Choi, Jin-Young Lee, Han-Kyu Lee, Hong-Won Suh.   

Abstract

Aspirin (ASA) is a widely used oral analgesic which acts as an inhibitor of cyclooxygenase. Acetaminophen (ACET) is also an effective analgesic and may selectively inhibit brain prostaglandin synthetase. Various proinflammatory cytokines injected into the central nervous system show pain behavior. In the present study, the effects of orally administered ASA and ACET on pain behaviors induced by various proinflammatory cytokines were examined. At a dose of 100 mg/kg, ASA or ACET did not affect the pain behavior induced by TNF-alpha (100 pg), IL-1beta (100 pg) or IFN-gamma (100 pg) administered intrathecally. However, at doses of 200 and 300 mg/kg, ASA or ACET significantly and dose-dependently attenuated pain behavior induced by TNF-alpha, IL-1beta or IFN-gamma administered intrathecally. Our results suggest that orally administered ASA and ACET produce antinociception by inhibiting the nociceptive action of TNF-alpha, IL-1beta or IFN-gamma administered intrathecally. 2005 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15775706     DOI: 10.1159/000084548

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  9 in total

1.  IFN-γ and TNF-α synergistically induce mesenchymal stem cell impairment and tumorigenesis via NFκB signaling.

Authors:  Lei Wang; Yinghua Zhao; Yi Liu; Kentaro Akiyama; Chider Chen; Cunye Qu; Yan Jin; Songtao Shi
Journal:  Stem Cells       Date:  2013-07       Impact factor: 6.277

2.  Aspirin treatment improved mesenchymal stem cell immunomodulatory properties via the 15d-PGJ2/PPARγ/TGF-β1 pathway.

Authors:  Jianxia Tang; Jimin Xiong; Tingting Wu; Zhangui Tang; Gang Ding; Chunmei Zhang; Songlin Wang; Yi Liu
Journal:  Stem Cells Dev       Date:  2014-07-01       Impact factor: 3.272

3.  [Preparation of aspirin sustained-release microsphere and its in vitro releasing property].

Authors:  Y Chen; Z N Liu; B Li; T Jiang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-10-18

4.  Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α.

Authors:  Yi Liu; Lei Wang; Takashi Kikuiri; Kentaro Akiyama; Chider Chen; Xingtian Xu; Ruili Yang; Wanjun Chen; Songlin Wang; Songtao Shi
Journal:  Nat Med       Date:  2011-11-20       Impact factor: 53.440

5.  Aspirin promotes bone marrow mesenchymal stem cell-based calvarial bone regeneration in mini swine.

Authors:  Yu Cao; Jimin Xiong; Shenghui Mei; Fu Wang; Zhigang Zhao; Songlin Wang; Yi Liu
Journal:  Stem Cell Res Ther       Date:  2015-10-31       Impact factor: 6.832

6.  Co-administration of aspirin and allogeneic adipose-derived stromal cells attenuates bone loss in ovariectomized rats through the anti-inflammatory and chemotactic abilities of aspirin.

Authors:  Hao Liu; Wei Li; Yunsong Liu; Xiao Zhang; Yongsheng Zhou
Journal:  Stem Cell Res Ther       Date:  2015-10-16       Impact factor: 6.832

7.  Establishing an osteoimmunomodulatory coating loaded with aspirin on the surface of titanium primed with phase-transited lysozyme.

Authors:  Wenxin Zhang; Xin Lu; Zuoying Yuan; Minjuan Shen; Yunjia Song; Huanhuan Liu; Jingjing Deng; Xue Zhong; Xu Zhang
Journal:  Int J Nanomedicine       Date:  2019-02-05

Review 8.  Systematic Review of Systemic and Neuraxial Effects of Acetaminophen in Preclinical Models of Nociceptive Processing.

Authors:  Hiroshi Hoshijima; Matthew Hunt; Hiroshi Nagasaka; Tony Yaksh
Journal:  J Pain Res       Date:  2021-11-12       Impact factor: 3.133

9.  Pain Controlling and Cytokine-regulating Effects of Lyprinol, a Lipid Extract of Perna Canaliculus, in a Rat Adjuvant-induced Arthritis Model.

Authors:  Chi-Ho Lee; John Hon-Kei Lum; Curtise Kin-Cheung Ng; Janice McKay; Yoki Kwok-Chu Butt; Man-Sau Wong; Samuel Chun-Lap Lo
Journal:  Evid Based Complement Alternat Med       Date:  2007-09-26       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.